Quick Answer
Spero Therapeutics, Inc. reported Total Revenue of $66.80 million for the year ending 2025.
- Spero Therapeutics, Inc. showed an increase of +430.8% in Total Revenue from 2025 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $140.0 thousand | Q2 2017: $249.0 thousand | Q3 2017: $597.0 thousand | Q4 2017: $993.0 thousand | Q1 2018: $1.15 million | Q2 2018: $463.0 thousand | Q3 2018: $658.0 thousand | Q4 2018: $1.69 million | Q1 2019: $3.81 million | Q1 2019: $7.72 million | Q2 2019: $67.0 thousand | Q2 2019: $2.16 million | Q3 2019: $4.64 million | Q3 2019: $172.0 thousand | Q4 2019: $696.0 thousand | Q1 2020: $1.70 million | Q1 2020: $169.0 thousand | Q2 2020: $1.73 million | Q2 2020: $51.0 thousand | Q3 2020: $38.0 thousand | Q3 2020: $4.00 million | Q1 2021: $7.30 million | Q2 2021: $2.11 million | Q2 2021: $5.15 million | Q3 2021: $3.06 million | Q3 2021: $708.0 thousand | Q1 2022: $247.0 thousand | Q1 2022: $2.07 million | Q2 2022: $896.0 thousand | Q2 2022: $1.99 million | Q3 2022: $2.01 million | Q3 2022: $1.08 million | Q1 2023: $2.07 million | Q1 2023: $223.0 thousand | Q2 2023: $269.0 thousand | Q2 2023: $2.72 million | Q3 2023: $25.47 million | Q3 2023: $218.0 thousand | Q1 2024: $9.27 million | Q1 2024: $140.0 thousand | Q2 2024: $10.20 million | Q2 2024: $114.0 thousand | Q3 2024: $13.47 million | Q3 2024: $65.0 thousand | Q1 2025: $12.0 thousand | Q1 2025: $5.87 million | Q2 2025: $0.00 | Q2 2025: $14.19 million | Q3 2025: $0.00 | Q3 2025: $5.44 million.
- Over the full 17 years of available data (2016 to 2025), Spero Therapeutics, Inc.'s Total Revenue has grown by 19,840.9%.
- Historical annual values: Fiscal year 2025: $66.80 million | Fiscal year 2025: $12.59 million | Fiscal year 2024: $371.0 thousand | Fiscal year 2024: $47.98 million | Fiscal year 2023: $933.0 thousand | Fiscal year 2023: $103.78 million | Fiscal year 2022: $53.51 million | Fiscal year 2022: $2.50 million | Fiscal year 2021: $3.07 million | Fiscal year 2021: $18.26 million | Fiscal year 2020: $9.33 million | Fiscal year 2020: $258.0 thousand | Fiscal year 2019: $18.15 million | Fiscal year 2019: $4.74 million | Fiscal year 2018: $3.97 million | Fiscal year 2017: $1.98 million | Fiscal year 2016: $335.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: